HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Jane Wasman, J.D. has been named Chief, Strategic Development. In this new role, Ms. Wasman will oversee the development and execution of the Company’s long-range strategic plans and objectives. She will also be responsible for the analysis of trends, developments and contingencies that may impact Acorda’s strategic courses of action, and for supporting and ensuring cross-functional integration among departments to achieve the Company's goals most effectively. Ms. Wasman will also continue with her current responsibilities as General Counsel, including management of the Company’s Legal, Compliance and Quality departments.
